AI assistant
Celldex Therapeutics, Inc. — Director's Dealing 2008
Mar 11, 2008
31801_dirs_2008-03-11_877fa823-2ebb-478a-82ce-8a25e7cf87f9.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AVANT IMMUNOTHERAPEUTICS INC (AVAN)
CIK: 0000744218
Period of Report: 2008-03-07
Reporting Person: PENNER HARRY JR (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2008-03-07 | Non-Qualified Stock Option | $47.25 | M | 416 | Acquired | 2008-05-12 | Common Stock (416) | Direct |
| 2008-03-07 | Non-Qualified Stock Option | $8.16 | A | 17728 | Acquired | 2015-03-07 | Common Stock (17728) | Direct |
Footnotes
F1: The option was previously reported as covering 5,000 shares at an exercise price of $3.9375 per share, but was adjusted to reflect the one-for-twelve reverse stock split that occurred on March 7, 2008.
F2: This option was granted for 212,739 shares at an exercise price of $0.68 per share, but was adjusted to reflect the one-for-twelve reverse stock split that occurred on March 7, 2008.
F3: 95,000 options granted under the AVANT 1999 Stock option and Incentive plan were cancelled according to their terms for no consideration on March 7, 2008.